PL3164380T3 - Inhibitory lizyno-specyficznej demetylazy-1 - Google Patents

Inhibitory lizyno-specyficznej demetylazy-1

Info

Publication number: PL3164380T3
Authority: PL; Poland
Prior art keywords: inhibitors; specific demethylase; lysine specific; lysine; demethylase
Prior art date: 2014-07-03

Application number

PL15814038T

Other languages

English (en)

Inventor

Young K. Chen

Toufike Kanouni

Zhe Nie

Jeffrey Alan Stafford

James Marvin Veal

Original Assignee

Celgene Quanticel Research, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-07-03

Filing date

2015-06-29

Publication date

2022-04-04

2015-06-29 Application filed by Celgene Quanticel Research, Inc. filed Critical Celgene Quanticel Research, Inc.

2022-04-04 Publication of PL3164380T3 publication Critical patent/PL3164380T3/pl

Links

KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title 1
239000004472 Lysine Substances 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Polyamides (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

PL15814038T 2014-07-03 2015-06-29 Inhibitory lizyno-specyficznej demetylazy-1 PL3164380T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462020886P	2014-07-03	2014-07-03
PCT/US2015/038345 WO2016003917A1 (en)	2014-07-03	2015-06-29	Inhibitors of lysine specific demethylase-1
EP15814038.4A EP3164380B1 (en)	2014-07-03	2015-06-29	Inhibitors of lysine specific demethylase-1

Publications (1)

Publication Number	Publication Date
PL3164380T3 true PL3164380T3 (pl)	2022-04-04

Family

ID=55019883

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL15814038T PL3164380T3 (pl)	2014-07-03	2015-06-29	Inhibitory lizyno-specyficznej demetylazy-1
PL19156976.3T PL3511319T3 (pl)	2014-07-03	2015-06-29	Inhibitory lizyno-specyficznej demetylazy-1

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL19156976.3T PL3511319T3 (pl)	2014-07-03	2015-06-29	Inhibitory lizyno-specyficznej demetylazy-1

Country Status (29)

Country	Link
US (3)	US9902719B2 (pl)
EP (2)	EP3511319B1 (pl)
JP (2)	JP6663866B2 (pl)
KR (1)	KR102475498B1 (pl)
CN (2)	CN108530424B (pl)
AU (1)	AU2015284383B2 (pl)
BR (1)	BR112017000043A2 (pl)
CA (1)	CA2954049A1 (pl)
CL (1)	CL2016003422A1 (pl)
CO (1)	CO2017000549A2 (pl)
CY (1)	CY1125127T1 (pl)
DK (2)	DK3511319T3 (pl)
EA (2)	EA201891526A3 (pl)
EC (1)	ECSP17006821A (pl)
ES (2)	ES2907676T3 (pl)
FI (1)	FI3511319T3 (pl)
HR (2)	HRP20220414T1 (pl)
HU (2)	HUE058852T2 (pl)
IL (2)	IL249881B (pl)
LT (2)	LT3164380T (pl)
MX (2)	MX395534B (pl)
PL (2)	PL3164380T3 (pl)
PT (2)	PT3511319T (pl)
RS (2)	RS63074B1 (pl)
SA (1)	SA517380651B1 (pl)
SG (2)	SG10201802501RA (pl)
SI (2)	SI3164380T1 (pl)
SM (2)	SMT202200136T1 (pl)
WO (1)	WO2016003917A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2987876A1 (en)	2015-06-12	2016-12-15	Oryzon Genomics, S.A.	Biomarkers associated with lsd1 inhibitors and uses thereof
WO2017013061A1 (en)	2015-07-17	2017-01-26	Oryzon Genomics, S.A.	Biomarkers associated with lsd1 inhibitors and uses thereof
ES3057783T3 (en)	2016-03-15	2026-03-04	Oryzon Genomics Sa	Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
WO2017158136A1 (en)	2016-03-16	2017-09-21	Oryzon Genomics, S.A.	Methods to determine kdm1a target engagement and chemoprobes useful therefor
US10150754B2 (en)	2016-04-19	2018-12-11	Celgene Quanticel Research, Inc.	Histone demethylase inhibitors
WO2018083189A1 (en)	2016-11-03	2018-05-11	Oryzon Genomics, S.A.	Biomarkers for determining responsiveness to lsd1 inhibitors
MX2020001323A (es)	2017-08-03	2020-03-20	Oryzon Genomics Sa	Metodos para tratar alteraciones del comportamiento.
LT3833670T (lt) *	2018-08-10	2024-06-25	Navire Pharma, Inc.	6-(4-amino-3-metil-2-oksa-8-azaspiro[4.5]dekan-8-il)-3-(2,3-dichlorfenil)-2-metilpirimidin-4(3h)-ono dariniai ir susiję junginiai kaip ptpn11 (shp2) inhibitoriai, skirti vėžiui gydyti
JP7532386B2 (ja)	2019-02-01	2024-08-13	ハンミファーマシューティカルズカンパニーリミテッド	イミダゾピリジン誘導体化合物及びその用途
KR102412632B1 (ko) *	2019-02-01	2022-06-24	한미약품 주식회사	이미다조피리딘 유도체 화합물 및 이의 용도
ES3053813T3 (en)	2019-03-20	2026-01-26	Oryzon Genomics Sa	Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
SG11202109159VA (en)	2019-03-20	2021-10-28	Oryzon Genomics Sa	Methods of treating borderline personality disorder
CN114341366A (zh)	2019-07-05	2022-04-12	奥莱松基因组股份有限公司	用于使用kdm1a抑制剂个体化治疗小细胞肺癌的生物标志物和方法
US11360505B2 (en)	2020-02-11	2022-06-14	Simmonds Precision Products, Inc.	Distributed network time synchronization
CN114105950B (zh) *	2020-08-31	2022-09-06	南京明德新药研发有限公司	吡唑类化合物及其应用
US20240199571A1 (en) *	2021-03-11	2024-06-20	Medshine Discovery Inc.	Thiophene compound and application thereof
CN117062813A (zh) *	2021-03-24	2023-11-14	四川汇宇制药股份有限公司	一种多环化合物及其应用
JP2024513260A (ja)	2021-04-08	2024-03-22	オリゾンジェノミックスソシエダッドアノニマ	骨髄癌処置のためのｌｓｄ１阻害剤の組み合わせ
CN116102533A (zh) *	2021-11-11	2023-05-12	中国科学院上海药物研究所	一种芳杂环类化合物及其应用
JP2025516648A (ja)	2022-05-09	2025-05-30	オリゾン・ゲノミクス・ソシエダッド・アノニマ	Ｌｓｄ１阻害薬を用いるｎｆ１変異腫瘍の治療法
CN119546292A (zh)	2022-05-09	2025-02-28	奥莱松基因组股份有限公司	使用lsd1抑制剂治疗恶性周围神经鞘瘤(mpnst)的方法
CN120529900A (zh)	2022-11-24	2025-08-22	奥莱松基因组股份有限公司	用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1963188A1 (de)	1969-12-17	1971-06-24	Bayer Ag	Neue Cyanphenyl-1,4-dihydropyridinderivate
AU2002214546A1 (en) *	2000-09-29	2002-04-08	Cor Therapeutics, Inc.	Bicyclic pyrimidin-4-one based inhibitors of factor xa
US7365069B2 (en) *	2002-04-10	2008-04-29	Bexel Pharmaceuticals Inc.	Pyrimidone derivatives
JP2005170792A (ja) *	2002-11-22	2005-06-30	Mitsubishi Pharma Corp	Ｌ−プロリン誘導体およびその医薬としての用途。
US7504423B2 (en)	2003-12-11	2009-03-17	Mitsubishi Tanabe Pharma Corporation	α-amino acid derivatives and use thereof as medicines
WO2006073167A1 (ja) *	2005-01-07	2006-07-13	Ono Pharmaceutical Co., Ltd.	ピロリジン誘導体
PL372332A1 (pl) *	2005-01-19	2006-07-24	ADAMED Sp.z o.o.	Nowe związki, pochodne kwasu 3-fenylopropionowego
WO2006129181A2 (en) *	2005-06-03	2006-12-07	Orchid Research Laboratories Limited	Preparation of 4-pyrimidone derivatives for treating inflammatory diseases
BRPI0615048A2 (pt) *	2005-09-01	2010-03-30	Lilly Co Eli	composto, composição farmacêutica, e, uso de um composto
JP2007197324A (ja)	2006-01-23	2007-08-09	Toray Ind Inc	２，４，５−置換−１，３−アゾール誘導体
WO2008021309A1 (en)	2006-08-15	2008-02-21	Wyeth	Imidazolidin-2-one derivatives useful as pr modulators
TW200815428A (en) *	2006-08-15	2008-04-01	Wyeth Corp	Oxazolidone derivatives as PR modulators
PE20081803A1 (es)	2007-03-09	2008-12-11	Wyeth Corp	Sintesis y caracterizacion de la forma ii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo
CL2008002793A1 (es) *	2007-09-20	2009-09-04	Cgi Pharmaceuticals Inc	Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
WO2009132310A1 (en) *	2008-04-25	2009-10-29	Wisconsin Alumni Research Foundation	Inhibitors of udp-galactopyranose mutase thwart mycobacterial growth
WO2011130515A1 (en)	2010-04-14	2011-10-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
WO2012009475A1 (en) *	2010-07-14	2012-01-19	Oregon Health & Science University	Methods of treating cancer with inhibition of lysine-specific demethylase 1
NZ629453A (en)	2012-03-06	2016-04-29	Lupin Ltd	Thiazole derivatives as alpha 7 nachr modulators
SI3080100T1 (sl) *	2013-12-11	2023-04-28	Celgene Quanticel Research, Inc.	Inhibitorji lizin specifične demetilaze-1
BR112016018691A2 (pt) *	2014-02-14	2017-08-08	Univ British Columbia	Compostos do domínio de ligação ao dna (dbd) de receptor de andrógeno humano como terapêuticos e métodos para seu uso
SI3137169T1 (sl) *	2014-05-01	2022-04-29	Celgene Quanticel Research, Inc.	Inhibitorji lizin specifične demetilaze-1
FR3020945B1 (fr)	2014-05-16	2016-05-06	Oreal	Composition pour colorer les fibres keratiniques comprenant une base d'oxydation et un coupleur heteroaryle particulier
RS60658B1 (sr) *	2014-06-27	2020-09-30	Celgene Quanticel Research Inc	Inhibitori lizin specifične demetilaze-1
US10414750B2 (en) *	2014-07-03	2019-09-17	Celgene Quanticel Research, Inc.	Inhibitors of lysine specific demethylase-1

2015
- 2015-06-29 EA EA201891526A patent/EA201891526A3/ru unknown
- 2015-06-29 HU HUE15814038A patent/HUE058852T2/hu unknown
- 2015-06-29 DK DK19156976.3T patent/DK3511319T3/da active
- 2015-06-29 EP EP19156976.3A patent/EP3511319B1/en active Active
- 2015-06-29 MX MX2020010900A patent/MX395534B/es unknown
- 2015-06-29 SG SG10201802501RA patent/SG10201802501RA/en unknown
- 2015-06-29 SI SI201531797T patent/SI3164380T1/sl unknown
- 2015-06-29 SI SI201531948T patent/SI3511319T1/sl unknown
- 2015-06-29 JP JP2016575768A patent/JP6663866B2/ja not_active Expired - Fee Related
- 2015-06-29 CN CN201810425583.0A patent/CN108530424B/zh not_active Expired - Fee Related
- 2015-06-29 CN CN201580047448.1A patent/CN106795103B/zh not_active Expired - Fee Related
- 2015-06-29 MX MX2017000168A patent/MX376207B/es active IP Right Grant
- 2015-06-29 LT LTEPPCT/US2015/038345T patent/LT3164380T/lt unknown
- 2015-06-29 RS RS20220311A patent/RS63074B1/sr unknown
- 2015-06-29 WO PCT/US2015/038345 patent/WO2016003917A1/en not_active Ceased
- 2015-06-29 EA EA201790085A patent/EA033698B1/ru not_active IP Right Cessation
- 2015-06-29 KR KR1020177003162A patent/KR102475498B1/ko active Active
- 2015-06-29 HU HUE19156976A patent/HUE062558T2/hu unknown
- 2015-06-29 RS RS20230452A patent/RS64423B1/sr unknown
- 2015-06-29 LT LTEP19156976.3T patent/LT3511319T/lt unknown
- 2015-06-29 PL PL15814038T patent/PL3164380T3/pl unknown
- 2015-06-29 EP EP15814038.4A patent/EP3164380B1/en active Active
- 2015-06-29 PT PT191569763T patent/PT3511319T/pt unknown
- 2015-06-29 CA CA2954049A patent/CA2954049A1/en not_active Abandoned
- 2015-06-29 SM SM20220136T patent/SMT202200136T1/it unknown
- 2015-06-29 ES ES15814038T patent/ES2907676T3/es active Active
- 2015-06-29 HR HRP20220414TT patent/HRP20220414T1/hr unknown
- 2015-06-29 AU AU2015284383A patent/AU2015284383B2/en not_active Ceased
- 2015-06-29 FI FIEP19156976.3T patent/FI3511319T3/fi active
- 2015-06-29 SG SG11201610975RA patent/SG11201610975RA/en unknown
- 2015-06-29 PT PT158140384T patent/PT3164380T/pt unknown
- 2015-06-29 BR BR112017000043-1A patent/BR112017000043A2/pt not_active Application Discontinuation
- 2015-06-29 DK DK15814038.4T patent/DK3164380T3/da active
- 2015-06-29 US US15/323,277 patent/US9902719B2/en active Active
- 2015-06-29 SM SM20230205T patent/SMT202300205T1/it unknown
- 2015-06-29 ES ES19156976T patent/ES2948782T3/es active Active
- 2015-06-29 HR HRP20230595TT patent/HRP20230595T1/hr unknown
- 2015-06-29 PL PL19156976.3T patent/PL3511319T3/pl unknown
2016
- 2016-12-30 CL CL2016003422A patent/CL2016003422A1/es unknown
2017
- 2017-01-01 IL IL249881A patent/IL249881B/en active IP Right Grant
- 2017-01-02 SA SA517380651A patent/SA517380651B1/ar unknown
- 2017-01-23 CO CONC2017/0000549A patent/CO2017000549A2/es unknown
- 2017-02-01 EC ECIEPI20176821A patent/ECSP17006821A/es unknown
2018
- 2018-01-10 US US15/867,397 patent/US10100046B2/en active Active
- 2018-09-05 US US16/122,703 patent/US20190002456A1/en not_active Abandoned
2019
- 2019-02-21 JP JP2019029856A patent/JP6768857B2/ja not_active Expired - Fee Related
2020
- 2020-01-19 IL IL272130A patent/IL272130B/en active IP Right Grant
2022
- 2022-04-11 CY CY20221100269T patent/CY1125127T1/el unknown

Also Published As

Publication number	Publication date
LT3511319T (lt)	2023-08-25
SA517380651B1 (ar)	2020-09-30
HUE058852T2 (hu)	2022-09-28
IL249881B (en)	2020-01-30
FI3511319T3 (fi)	2023-07-20
ES2948782T3 (es)	2023-09-19
JP2019108346A (ja)	2019-07-04
IL272130A (en)	2020-03-31
EP3164380A4 (en)	2018-07-18
MX395534B (es)	2025-03-25
SI3511319T1 (sl)	2023-10-30
EP3511319B1 (en)	2023-05-03
BR112017000043A2 (pt)	2018-07-17
EA201790085A1 (ru)	2017-08-31
CN108530424B (zh)	2021-10-01
DK3511319T3 (da)	2023-07-31
EA201891526A2 (ru)	2018-12-28
US10100046B2 (en)	2018-10-16
US20180127408A1 (en)	2018-05-10
HRP20220414T1 (hr)	2022-05-27
ES2907676T3 (es)	2022-04-26
IL249881A0 (en)	2017-03-30
CN106795103B (zh)	2019-07-12
ECSP17006821A (es)	2017-03-31
EA033698B1 (ru)	2019-11-18
EP3164380B1 (en)	2022-02-09
IL272130B (en)	2021-03-25
MX2020010900A (es)	2022-09-13
SG11201610975RA (en)	2017-01-27
KR102475498B1 (ko)	2022-12-07
HRP20230595T1 (hr)	2023-09-15
PT3511319T (pt)	2023-06-29
JP6663866B2 (ja)	2020-03-13
HUE062558T2 (hu)	2023-11-28
LT3164380T (lt)	2022-06-27
SI3164380T1 (sl)	2022-06-30
CA2954049A1 (en)	2016-01-07
SMT202200136T1 (it)	2022-05-12
EP3511319A1 (en)	2019-07-17
CL2016003422A1 (es)	2017-11-10
EP3164380A1 (en)	2017-05-10
AU2015284383B2 (en)	2019-04-18
WO2016003917A1 (en)	2016-01-07
CO2017000549A2 (es)	2017-04-20
EA201891526A3 (ru)	2019-05-31
RS64423B1 (sr)	2023-09-29
US9902719B2 (en)	2018-02-27
DK3164380T3 (da)	2022-03-28
CN108530424A (zh)	2018-09-14
SG10201802501RA (en)	2018-05-30
KR20170018100A (ko)	2017-02-15
AU2015284383A1 (en)	2017-02-02
JP2017525668A (ja)	2017-09-07
SMT202300205T1 (it)	2023-09-06
PT3164380T (pt)	2022-03-02
US20190002456A1 (en)	2019-01-03
US20170129882A1 (en)	2017-05-11
MX2017000168A (es)	2017-05-01
CN106795103A (zh)	2017-05-31
PL3511319T3 (pl)	2023-09-11
RS63074B1 (sr)	2022-04-29
CY1125127T1 (el)	2024-02-16
MX376207B (es)	2025-03-07
JP6768857B2 (ja)	2020-10-14

Publication	Publication Date	Title
IL272130B (en)	2021-03-25	Inhibitors of specific lysine demethylase-1
IL250876B (en)	2021-09-30	Inhibitors of specific lysine demethylase-1
ZA201607613B (en)	2017-11-29	Inhibitors of lysine specific demethylase-1
ZA201700069B (en)	2018-04-25	Inhibitors of lysine specific demethylase-1
ZA201700072B (en)	2018-04-25	Inhibitors of lysine specific demethylase-1
HUE050876T2 (hu)	2021-01-28	A lizin gingipain inhibitorai
HK1234047A1 (en)	2018-02-09	Inhibitors of lysine specific demethylase-1
HK1231134A1 (en)	2017-12-15	Inhibitors of lysine specific demethylase-1
HK1231843A1 (en)	2017-12-29	Inhibitors of lysine specific demethylase-1